Fennec PharmaceuticalsFENC
NASDAQBiotech
$10.63+0.28%
No cached AI snapshot yet for FENC.
Be the first to run a multi-agent analysis on this ticker.
Key Stats
$225.47MMarket cap
$9.9252-week high
$5.5852-week low
210,216Avg volume (30d)
35 employees34.48M shares outstandinglisted 2002-01-28
Next earnings ~May 5, 2026
About Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
Latest News
Showing market-wide stock news
Bitcoin retreats after crypto bill setback, Fed next
This BlackRock strategist opposes a Fed hike. Here are the funds she recommends.
Gold outlook hinges on Fed signals; metal could test $4,200: Kotak Sec
US Dollar: Higher yields and oil support – MUFG
Bond Investors Are on Edge. Here's Why Stock Investors Should Pay Attention.
Wall St futures edge higher in countdown to Fed decision
Related Stocksin Biotech
Ready to see the live AI view on FENC?
Launch a real-time multi-agent room — Claude, GPT, Gemini, DeepSeek, Grok, and Qwen analyzing FENC side-by-side with live signals.